News : ox17

Uppsala, February 17, 2010

Orexo AB (publ) –
Year-end Report January–December 2009



Key events during the year
• Net revenues totaled MSEK 236.1 (233.3).
• The loss after tax was MSEK 98.1 (loss: 103.1).
• The loss per share amounted to a loss of SEK 4.32 (loss: 4.77).
• Cash and cash equivalents at year-end totaled MSEK 87.4 (188.2).
• Abstral was launched in UK, Germany, France, Spain and Greece.
• In March,...

Uppsala, November 10, 2009

Orexo AB (publ) – Interim report January-September 2009


Key events during the period
• Net revenues amounted to MSEK 208.2 (141.2).
• The loss after tax was MSEK 40.1 (loss: 88,6).
• The loss per share was SEK 1.78 (loss: 4.10).
• Cash and cash equivalents at the end of the quarter totaled MSEK 107.1 (195.7).
• In March, the US Food and Drug Administration (FDA) approved Orexo’s Edluar...

Uppsala, Sweden, 28 August, 2009 - Orexo (STO: ORX) announces it has signed an exclusive worldwide licensing agreement with a Novartis affiliate to develop and commercialise a novel product related to Orexo’s OX17 program.

Under the terms of the agreement, Novartis will fund all future development of the new product and will receive an exclusive license to all related intellectual property. Orexo will receive...

Orexo has signed an exclusive development agreement with a large healthcare company, providing for joint development within Orexo’s OX17 program for gastroesophageal reflux disease (GERD), and will be discontinuing all other licensing discussions for Ox17.

During this development work, Orexo will continue negotiations to enter into an appropriate global exclusive license agreement including the whole of Orexo’s...